Keywords: introgen, ingn, ph, ii, melanoma, firm, therapeutics

Introgen's INGN 241 in Ph II for melanoma

Article | 19 April 2004

Print This

US firm Introgen Therapeutics has initiated a Phase II trial of its INGN 241 in patients with metastatic melanoma. The product ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in